Clinical trials: Rectal Cancers
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer.
- Trial name
- NCT01399190
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 9 sites in Slovakia
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Advanced Malignancy, Advanced Solid Tumors
Safety Study of AMG 228 to Treat Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT02437916
- Testing
- AMG 228
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Amgen
Colorectal Cancer
Paired Analysis of Sensitivity for Colorectal Cancer Using COLVERA : PASCAL
To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in subjects with colorectal cancer that have documented recurrence or no evidence…
- Trial name
- PASCAL (NCT03706248)
- Testing
- Blood Draw
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Clinical Genomics Pathology
Rectal Neoplasms
A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.
The purpose of this study is to help answer the following research questions: If the study drug Pemetrexed can help patients with rectal cancer; If molecular biological parameters are correlated respectively changing due to…
- Trial name
- NCT00330915
- Testing
- pemetrexed
- Where
- Sweden
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Cancer
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
We intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex fluorescence PCR.
- Trial name
- NCT05685524
- Testing
- DNA methylation test
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer in Patients Under 50 Years of Age, Colorectal Cancer
Colorectal Cancer in Young Adults: Study of Incidence, Survival, and Prognostic Factors in Tarragona, Spain
We conducted an observational, descriptive, longitudinal and retrospective study of 59 patients under 50 years of age diagnosed with CRC in the province of Tarragona, between 2019 and 2024.
- Trial name
- CCR50 (NCT07026955)
- Testing
- colorectal cancer in patients over 50 years of age
- Where
- Spain
- Volunteers
- 59 people
- Sponsor
- HJ23
Metastatic Colorectal Cancer
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous…
- Trial name
- NCT07543744
- Testing
- RPH-030, Vectibix®, Irinotecan
- Where
- 26 sites in Russia
- Volunteers
- 180 people
- Sponsor
- R-Pharm
Metastatic Colorectal Cancer, Skin Rash
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with…
- Conditions
- Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities, Colon Cancer
- Trial name
- STEPP (NCT00332163)
- Testing
- Panitumumab, Irinotecan, FOLFIRI
- Volunteers
- 95 people
- Sponsor
- Amgen
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
Colorectal Neoplasms
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
After consultation with the Korean Health Authorities, the two Post-Authorization Safety Studies EMR 62202-509 (NCT01082315) and EMR 62241-508 (NCT01075828) were combined within one study protocol EMR 062202-551.
- Trial name
- NCT01082315
- Testing
- Erbitux (Cetuximab)
- Where
- South Korea
- Volunteers
- 730 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
This randomized, open-label study will evaluate the safety and efficacy of Avastin (Bevacizumab) added to standard mFOLFOX6 chemotherapy in treatment-naïve patients with Stage IV metastatic colorectal cancer.
- Trial name
- NCT01338558
- Testing
- bevacizumab [Avastin], cetuximab, mFOLFOX6
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Solid Tumors
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.
- Trial name
- NCT05731947
- Testing
- Revumenib, Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Syndax Pharmaceuticals
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Advanced or Metastatic Colorectal Cancer (mCRC)
Individual Patient Expanded Access to CA102N
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
- Trial name
- NCT05274204
- Testing
- CA102N
- Sponsor
- Holy Stone Healthcare Co., Ltd
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Colorectal Cancer, Head and Neck Cancer
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT00820417
- Testing
- Cetuximab/Gefitinib combination and/or monotherapy
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 63 people
- Sponsor
- Harrison Clinical Research
Colorectal Cancer
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Monotherapy treatment with CS-7017 to assess progression-free-survival (PFS) of subjects who achieved an objective response of Disease Control on first line therapy with Folinic acid (leucovorin), Fluorouracil (5-FU), Oxaliplatin…
- Trial name
- NCT00986440
- Testing
- CS-7017
- Where
- 39 sites in Czechia, France and 7 more
- Volunteers
- 84 people
- Sponsor
- Daiichi Sankyo
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with…
- Trial name
- NCT04793958
- Testing
- MRTX849, Cetuximab, mFOLFOX6 Regimen
- Where
- 419 sites in United States, Argentina and 30 more
- Volunteers
- 461 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.